Trevena, Inc. Promotes Carrie L. Bourdow from Senior Vice President and Chief Commercial Officer to Executive Vice President and Chief Operating Officer
February 02, 2018 at 12:00 pm
Share
Trevena, Inc. announced the promotion of Carrie L. Bourdow from Senior Vice President and Chief Commercial Officer to Executive Vice President and Chief Operating Officer, effective immediately. Ms. Bourdow brings to this newly created position over 25 years of experience at large and small commercial biopharmaceutical companies. Ms. Bourdow joined the company as Senior Vice President and Chief Commercial Officer in May 2015. Prior to joining the company, she was vice president of marketing, reimbursement, and operations at Cubist Pharmaceuticals, Inc., from 2013 to 2015, where she had responsibility for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companyâs pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
Trevena, Inc. Promotes Carrie L. Bourdow from Senior Vice President and Chief Commercial Officer to Executive Vice President and Chief Operating Officer